Since, as described above, the triple negative MDA-MB-231 breast cancer cells are sensitive to rosiglitazone, we also studied whether the inhibition of ACSL4 activity could reverse ER therapy resistance in cells that do not express ER. The gene discussed is ACSL4; the disease is breast carcinoma.